Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41.

The novel virucidal protein cyanovirin-N (CV-N) binds with equally high affinity to soluble forms of either H9 cell-produced or recombinant glycosylated HIV-1 gp120 (sgp120) or gp160 (sgp160). Fluorescence polarization studies showed that CV-N is also capable of binding to the glycosylated ectodomain of the HIV-envelope protein gp41 (sgp41) (as well as SIV glycoprotein 32), albeit with considerably lower affinity than the sgp120/CV-N interaction. Pretreatment of CV-N with either sgp120 or sgp41 abrogated the neutralizing activity of CV-N against intact, infectious HIV-1 virions. Isothermal calorimetry and optical biosensor binding studies showed that CV-N bound to recombinant sgp120 with a K(d) value ranging from 2 to 45 nM and to sgp41 with a K(d) value of 606 nM; furthermore, they indicated an approximate 5:1 stoichiometry for CV-N binding to sgp120 and a 1:1 stoichiometry for CV-N binding to sgp41. Circular dichroism studies additionally illuminated the binding of CV-N with both sgp120 and sgp41, providing the first direct evidence that conformational changes are a consequence of CV-N interactions with both HIV-1 envelope glycoproteins.

[1]  Thomas,et al.  Diversity of Oligosaccharide Structures on the Envelope Glycoprotein gp 120 of Human Immunodeficiency Virus 1 from the Lymphoblastoid Cell Line H 9 , 2001 .

[2]  M. Boyd,et al.  Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses , 2000, Journal of Virology.

[3]  M. Boyd,et al.  Siamenol, a new carbazole alkaloid from Murraya siamensis. , 2000, Journal of natural products.

[4]  E. Toone,et al.  On the Meaning of Affinity:  Cluster Glycoside Effects and Concanavalin A , 1999 .

[5]  P. S. Kim,et al.  Inhibiting HIV-1 Entry Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket , 1999, Cell.

[6]  E. Freire,et al.  The effect of inhibitor binding on the structural stability and cooperativity of the HIV‐1 protease , 1999, Proteins.

[7]  A. Gronenborn,et al.  Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. , 1999, Journal of molecular biology.

[8]  Q. Sattentau,et al.  Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120 , 1999, Journal of Virology.

[9]  K. Nagashima,et al.  The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding. , 1998, Biochemical and biophysical research communications.

[10]  A. Gronenborn,et al.  Solution structure of cyanovirin-N, a potent HIV-inactivating protein , 1998, Nature Structural Biology.

[11]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[12]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[13]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[14]  R. Whittaker,et al.  Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion. , 1998, AIDS research and human retroviruses.

[15]  L. Pannell,et al.  Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. , 1998, Protein expression and purification.

[16]  Christos,et al.  Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Gustafson,et al.  Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells. , 1997, Biochemical and biophysical research communications.

[18]  L. Pannell,et al.  Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. , 1997, Biochemical and Biophysical Research Communications - BBRC.

[19]  L. Pannell,et al.  Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. , 1997, Biochemical and biophysical research communications.

[20]  L K Pannell,et al.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.

[21]  John P. Devlin,et al.  High Throughput Screening: The Discovery of Bioactive Substances , 1997 .

[22]  K. Guthrie,et al.  HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. , 1996, Biochemistry.

[23]  J. Ladbury,et al.  Sensing the heat: the application of isothermal titration calorimetry to thermodynamic studies of biomolecular interactions. , 1996, Chemistry & biology.

[24]  P. Earl,et al.  The ectodomain of HIV‐1 env subunit gp41 forms a soluble, alpha‐helical, rod‐like oligomer in the absence of gp120 and the N‐terminal fusion peptide. , 1996, The EMBO journal.

[25]  E. Freed,et al.  The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection (*) , 1995, The Journal of Biological Chemistry.

[26]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Cummings,et al.  Site-specific N-glycosylation and oligosaccharide structures of recombinant HIV-1 gp120 derived from a baculovirus expression system. , 1993, Biochemistry.

[28]  M. A. Andrade,et al.  Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. , 1993, Protein engineering.

[29]  T. Oas,et al.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Boyd,et al.  A semiautomated multiparameter approach for anti-HIV drug screening. , 1991, Journal of virological methods.

[31]  K. Titani,et al.  Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. , 1990, The Journal of biological chemistry.

[32]  J. Schneider,et al.  Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. , 1988, The Journal of biological chemistry.

[33]  M. Gonda,et al.  Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. , 1987, AIDS research and human retroviruses.